Patient characteristics
| Factors . | All patients . | With gilteritinib . | Without gilteritinib . | P value . |
|---|---|---|---|---|
| n = 25 . | n = 14 . | n = 11 . | ||
| Age, y (median [range]) | 52 (25-72) | 50 (32-72) | 53 (25-70) | .94 |
| Transplantation years before 2018, n (%) | 6 (24%) | 2 (14.3) | 4 (36.4) | .35 |
| Conventional karyotype, n (%) | ||||
| Normal karyotype | 17 (68.0) | 10 (71.4) | 7 (63.6) | 1.00 |
| FLT3-ITD/TKD, n (%) | ||||
| ITD | 20 (80.0) | 11 (78.6) | 9 (81.8) | 1.00 |
| TKD | 3 (12.0) | 2 (14.3) | 1 (9.1) | |
| Both | 2 (8.0) | 1 (7.1) | 1 (9.1) | |
| Prior administration of FLT3-inhibitor before HSCT, n (%) | ||||
| Yes | 19 (76.0) | 14 (100) | 5 (45.5) | .003 |
| AML status at HSCT, n (%) | ||||
| CR, MRD-negative | 6 (24.0) | 2 (14.3) | 3 (27.3) | .28 |
| CR, MRD-positive | 12 (48.0) | 10 (71.4) | 4 (36.4) | |
| Non-CR | 6 (24.0) | 2 (14.3) | 4 (36.4) | |
| No. of HSCT, n (%) | ||||
| First HSCT | 19 (76.0) | 11 (78.6) | 8 (72.7) | .79 |
| Second HSCT | 5 (20.0) | 2 (14.3) | 3 (27.3) | |
| Third HSCT | 1 (4.0) | 1 (7.1) | 0 (0.0) | |
| Conditioning intensity, n (%) | ||||
| MAC | 17 (68.0) | 9 (64.3) | 8 (72.7) | 1 |
| HCT-CI (%)∗ | ||||
| 0 | 4 (20.0) | 2 (16.7) | 2 (25.0) | .88 |
| 1 | 11 (55.0) | 6 (50.0) | 5 (62.5) | |
| 2 | 2 (10.0) | 1 (8.3) | 1 (12.5) | |
| ≥3 | 3 (15.0) | 3 (27.3) | 0 (0.0) | |
| Donor selection, n (%) | ||||
| 8 of 8 matched related | 5 (20.0) | 3 (21.4) | 2 (18.2) | .85 |
| 8 of 8 matched unrelated | 3 (12.0) | 1 (7.1) | 2 (18.2) | |
| 7 of 8 mismatched unrelated | 1 (4.0) | 1 (7.1) | 0 (0.0) | |
| ≤ 6 of 8 haploidentical | 7 (28.0) | 3 (21.4) | 4 (36.4) | |
| Cord blood | 9 (36.0) | 6 (42.9) | 3 (27.3) | |
| CD34+cells/CB unit (median 106cells [range]) | 1.11 (0.80-1.83) | 1.06 (0.80-1.83) | 1.29 (0.96-1.31) | .44 |
| Bridging chemotherapy before HSCT, n (%) | ||||
| Gilteritinib | 10 (40.0) | 8 (57.1) | 2 (18.2) | .05 |
| Quizartinib | 1 (4.0) | 1 (7.1) | 0 (0.0) | |
| Gilteritinib + α† | 2 (8.0) | 2 (14.3) | 0 (0.0) | |
| Intensive chemotherapy | 6 (24.0) | 2 (14.3) | 4 (36.4) | |
| Low-dose chemotherapy | 4 (20.0) | 1 (7.1) | 3 (27.3) | |
| None | 2 (10.0) | 0 (0.0) | 2 (18.2) | |
| Post-HSCT status at day 28-45, n (%) | ||||
| CR, MRD-negative | 8 (32.0) | 3 (21.4) | 5 (45.5) | .14 |
| CR, MRD-positive | 16 (64.0) | 11 (78.6) | 5 (45.5) | |
| CR, not MRD-evaluated | 1 (4.0) | 0 (0.0) | 1 (9.1) |
| Factors . | All patients . | With gilteritinib . | Without gilteritinib . | P value . |
|---|---|---|---|---|
| n = 25 . | n = 14 . | n = 11 . | ||
| Age, y (median [range]) | 52 (25-72) | 50 (32-72) | 53 (25-70) | .94 |
| Transplantation years before 2018, n (%) | 6 (24%) | 2 (14.3) | 4 (36.4) | .35 |
| Conventional karyotype, n (%) | ||||
| Normal karyotype | 17 (68.0) | 10 (71.4) | 7 (63.6) | 1.00 |
| FLT3-ITD/TKD, n (%) | ||||
| ITD | 20 (80.0) | 11 (78.6) | 9 (81.8) | 1.00 |
| TKD | 3 (12.0) | 2 (14.3) | 1 (9.1) | |
| Both | 2 (8.0) | 1 (7.1) | 1 (9.1) | |
| Prior administration of FLT3-inhibitor before HSCT, n (%) | ||||
| Yes | 19 (76.0) | 14 (100) | 5 (45.5) | .003 |
| AML status at HSCT, n (%) | ||||
| CR, MRD-negative | 6 (24.0) | 2 (14.3) | 3 (27.3) | .28 |
| CR, MRD-positive | 12 (48.0) | 10 (71.4) | 4 (36.4) | |
| Non-CR | 6 (24.0) | 2 (14.3) | 4 (36.4) | |
| No. of HSCT, n (%) | ||||
| First HSCT | 19 (76.0) | 11 (78.6) | 8 (72.7) | .79 |
| Second HSCT | 5 (20.0) | 2 (14.3) | 3 (27.3) | |
| Third HSCT | 1 (4.0) | 1 (7.1) | 0 (0.0) | |
| Conditioning intensity, n (%) | ||||
| MAC | 17 (68.0) | 9 (64.3) | 8 (72.7) | 1 |
| HCT-CI (%)∗ | ||||
| 0 | 4 (20.0) | 2 (16.7) | 2 (25.0) | .88 |
| 1 | 11 (55.0) | 6 (50.0) | 5 (62.5) | |
| 2 | 2 (10.0) | 1 (8.3) | 1 (12.5) | |
| ≥3 | 3 (15.0) | 3 (27.3) | 0 (0.0) | |
| Donor selection, n (%) | ||||
| 8 of 8 matched related | 5 (20.0) | 3 (21.4) | 2 (18.2) | .85 |
| 8 of 8 matched unrelated | 3 (12.0) | 1 (7.1) | 2 (18.2) | |
| 7 of 8 mismatched unrelated | 1 (4.0) | 1 (7.1) | 0 (0.0) | |
| ≤ 6 of 8 haploidentical | 7 (28.0) | 3 (21.4) | 4 (36.4) | |
| Cord blood | 9 (36.0) | 6 (42.9) | 3 (27.3) | |
| CD34+cells/CB unit (median 106cells [range]) | 1.11 (0.80-1.83) | 1.06 (0.80-1.83) | 1.29 (0.96-1.31) | .44 |
| Bridging chemotherapy before HSCT, n (%) | ||||
| Gilteritinib | 10 (40.0) | 8 (57.1) | 2 (18.2) | .05 |
| Quizartinib | 1 (4.0) | 1 (7.1) | 0 (0.0) | |
| Gilteritinib + α† | 2 (8.0) | 2 (14.3) | 0 (0.0) | |
| Intensive chemotherapy | 6 (24.0) | 2 (14.3) | 4 (36.4) | |
| Low-dose chemotherapy | 4 (20.0) | 1 (7.1) | 3 (27.3) | |
| None | 2 (10.0) | 0 (0.0) | 2 (18.2) | |
| Post-HSCT status at day 28-45, n (%) | ||||
| CR, MRD-negative | 8 (32.0) | 3 (21.4) | 5 (45.5) | .14 |
| CR, MRD-positive | 16 (64.0) | 11 (78.6) | 5 (45.5) | |
| CR, not MRD-evaluated | 1 (4.0) | 0 (0.0) | 1 (9.1) |